perrycomo schreef op 29 februari 2016 14:21:
Sijmen de Vries, Pharming’s CEO, commented: “Pharming supports Rare Disease Day to recognise the many patients around the world living with the burden of such diseases. As an R&D company, we are working diligently, through our technology platform, to find new solutions, not only for HAE but also for Pompe? and Fabry diseases, for which there are significant unmet medical needs. Through RUCONEST®, we are providing a safe and efficacious non- blood derived (recombinant) enzyme replacement therapy for HAE patients in countries where the treatment is approved and available and through the international HAE patients organization’s (HAEi) Global Access Plan (HAEi-GAP) in the rest of the world.”
Mooi toch .Ik hoop met pharming dat de non blood-derived products een steeds groter aandeel gaan hebben in zeldzame aandoeningen als o.a.hae